PROCEPT BioRobotics Q2 revenue up 48% YoY to $79.2mln.

• PROCEPT BioRobotics reports Q2 2025 revenue of $79.2 million, up 48% YoY. • U.S. handpiece and consumables revenue increased by 58% to $43.1 million. • 51 robotic systems sold in Q2 2025. • U.S. system and rental revenue rose 24% to $22.1 million. • The company increased its 2025 revenue guidance.

PROCEPT BioRobotics (Nasdaq: PRCT) reported robust financial results for the second quarter of 2025, with total revenue reaching $79.2 million, representing a 48% year-over-year (YoY) increase. The company's U.S. revenue grew 46% to $69.6 million, driven by system sales and increased handpiece revenue. International revenue surged 69% to $9.6 million, indicating successful market penetration beyond the U.S. [1]

Key highlights include 51 new U.S. robotic system sales and an expanded U.S. install base of 595 systems. Gross margin improved to 65% from 59% year-over-year. The company increased its 2025 revenue guidance to $325.5 million, representing 45% growth. Additionally, PROCEPT announced the appointment of Larry Wood as CEO, effective September 2, 2025.

The performance was driven by strong adoption across all segments, particularly in U.S. handpiece and consumables revenue, which grew 58% to $43.1 million. The company's margin profile is showing significant improvement, with gross margin expanding to 65% from 59% in the year-ago period. This 600 basis point improvement reflects better operational efficiencies, overhead absorption, and higher average selling prices on robotic systems—all positive signs of scaling economics as the company grows.

PROCEPT's U.S. commercial strategy appears to be working exceptionally well. They sold 51 robotic systems in the U.S. during the quarter, bringing their installed base to 595 systems—a critical metric as each system placement drives recurring revenue through handpiece and consumable sales. The 24% growth in U.S. system revenue to $22.1 million coupled with the faster 58% growth in consumables suggests increasing utilization rates per system.

International expansion is also accelerating, with international revenue surging 69% to $9.6 million, indicating successful market penetration beyond the U.S. While still operating at a loss, PROCEPT's financial trajectory is improving substantially. Net loss narrowed to $19.6 million from $25.6 million in the prior year, and Adjusted EBITDA loss improved to $8.0 million from $17.9 million—a 55% improvement that suggests a clear path toward profitability as revenue continues to scale.

The company's balance sheet remains strong with $305.8 million in cash and cash equivalents against $52.0 million in long-term borrowings, providing ample runway to fund growth initiatives including the WATER IV prostate cancer study. Management's decision to raise full-year 2025 revenue guidance to $325.5 million (from $323.0 million) signals confidence in sustained momentum. With gross margin expected to reach approximately 64.5% for the full year, PROCEPT is demonstrating both strong top-line growth and improving operational efficiency.

PROCEPT BioRobotics will host a conference call to discuss the second quarter 2025 financial results on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links.

References:
[1] https://www.stocktitan.net/news/PRCT/procept-bio-robotics-reports-second-quarter-2025-financial-results-s94veakyikgh.html